| Style | Citing Format |
|---|---|
| MLA | Askari H, et al.. "A Glance at the Therapeutic Potential of Irisin Against Diseases Involving Inflammation, Oxidative Stress, and Apoptosis: An Introductory Review." Pharmacological Research, vol. 129, no. , 2018, pp. 44-55. |
| APA | Askari H, Rajani SF, Poorebrahim M, Haghiaminjan H, Raeisabdollahi E, Abdollahi M (2018). A Glance at the Therapeutic Potential of Irisin Against Diseases Involving Inflammation, Oxidative Stress, and Apoptosis: An Introductory Review. Pharmacological Research, 129(), 44-55. |
| Chicago | Askari H, Rajani SF, Poorebrahim M, Haghiaminjan H, Raeisabdollahi E, Abdollahi M. "A Glance at the Therapeutic Potential of Irisin Against Diseases Involving Inflammation, Oxidative Stress, and Apoptosis: An Introductory Review." Pharmacological Research 129, no. (2018): 44-55. |
| Harvard | Askari H et al. (2018) 'A Glance at the Therapeutic Potential of Irisin Against Diseases Involving Inflammation, Oxidative Stress, and Apoptosis: An Introductory Review', Pharmacological Research, 129(), pp. 44-55. |
| Vancouver | Askari H, Rajani SF, Poorebrahim M, Haghiaminjan H, Raeisabdollahi E, Abdollahi M. A Glance at the Therapeutic Potential of Irisin Against Diseases Involving Inflammation, Oxidative Stress, and Apoptosis: An Introductory Review. Pharmacological Research. 2018;129():44-55. |
| BibTex | @article{ author = {Askari H and Rajani SF and Poorebrahim M and Haghiaminjan H and Raeisabdollahi E and Abdollahi M}, title = {A Glance at the Therapeutic Potential of Irisin Against Diseases Involving Inflammation, Oxidative Stress, and Apoptosis: An Introductory Review}, journal = {Pharmacological Research}, volume = {129}, number = {}, pages = {44-55}, year = {2018} } |
| RIS | TY - JOUR AU - Askari H AU - Rajani SF AU - Poorebrahim M AU - Haghiaminjan H AU - Raeisabdollahi E AU - Abdollahi M TI - A Glance at the Therapeutic Potential of Irisin Against Diseases Involving Inflammation, Oxidative Stress, and Apoptosis: An Introductory Review JO - Pharmacological Research VL - 129 IS - SP - 44 EP - 55 PY - 2018 ER - |